1Schiller JH. Current standards of care in small-cell and non-small-cell lung cancer[ J]. Oncology,2001,61 ( Suppl. 1 ):3 -13.
2Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: Phase Ⅲ trial of Southeastern Cancer Study Group[J]. J Clin Oncol, 1992,10:282 -291.
3Lassen U, Osterlind K, Hansen M, et al. Long-term survival in snall-cell lung cancer: posttreatment characteristics in patients surviving 5-18 + years-an anal-ysis of 1714 consecutive patients[J]. J Clin Oncol, 1995,13:1215 - 1220.
4Schutte W. Chemotherapy as treatment of primary and recurrent small cell lung cancer[ J ]. Lung Cancer, 2001, S99 -107.
5Grant SC, Gralla R,J, Kriss MG, et al.Single agent chemotherapy trials in small cell lung cancer, 1970 - 1990:The case for studies in previously treated patients[J]. J Clin Oncol, 1992,10:484 - 498.
6Giaccone G. Second line chemotherapy in small cell lung cancer [ J ]. Lung Cancer, 1989,5:207 - 213.
7Figoli F, Veronesi A, Ardizzoni A, et al. Cisplatin and etoposide as second line chemotherapy in patients with small cell lung cancer [ J ]. Cancer Invest,1998,6:1 -5.
8Albain KS, Crowley JJ, Hutchins L, et al. Predictors of survival following relapse or progression of small cell lung cancer. Southwest Oncology Group Study 8605 report and analysis of recurrent disease data base [ J ]. Cancer,1993 ,72:1184 - 1191.
9Rocha-Lima CM, Chiappori A. Treatment of relapsed small-cell lung cancer-a focus on the evolving role of topotecan[J]. Lung Cancer, 2003,40:229- 236.
10yon Pawel J, Asklepios F, Ganting BM, et al. The role of topotecan in treating small cell lung cancer: second-line treatment[J]. Lung Cancer,2003,41 ( Suppl. 4): S3 - 8.
